Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

ClinicalTrials.gov ID: NCT05119920

Public ClinicalTrials.gov record NCT05119920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream BID for the Treatment of Signs and Symptoms of Dry Eye Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.

Study identification

NCT ID: NCT05119920
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Glaukos Corporation; Industry
Enrollment: 226 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2022 (Actual)
Primary completion: Jul 27, 2022 (Actual)
Completion: Jul 27, 2022 (Actual)
Last update posted: Jul 12, 2023

2022

United States locations

U.S. sites: 19
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
Glaukos Investigator	Chandler	Arizona	85224	—
Glaukos Investigator	Sun City	Arizona	85351	—
Glaukos Investigator	Glendale	California	91204	—
Glaukos Investigator	Mission Hills	California	91345	—
Glaukos Investigator	Newport Beach	California	92663	—
Glaukos Investigator	Petaluma	California	94954	—
Glaukos Investigator	Rancho Cordova	California	95670	—
Glaukos Investigator	Grand Junction	Colorado	81501	—
Glaukos Investigator	Fort Myers	Florida	33901	—
Glaukos Investigator	Roswell	Georgia	30076	—
Glaukos Investigator	St Louis	Missouri	63131	—
Glaukos Investigator	Henderson	Nevada	89052	—
Glaukos Investigator	Rochester	New York	14618	—
Glaukos Investigator	Cranberry Township	Pennsylvania	16066	—
Glaukos Investigator	Memphis	Tennessee	38119	—
Glaukos Investigator	Nashville	Tennessee	37215	—
Glaukos Investigator	Houston	Texas	77025	—
Glaukos Investigator	San Antonio	Texas	78229	—
Glaukos Investigator	Lynchburg	Virginia	24502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05119920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 12, 2023 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05119920 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →